A Chinese single-center retrospective cohort assessed whether HIV infection independently associates with incident short-term major adverse cardiovascular events (MACE) in patients who already had ultrasound-confirmed carotid atherosclerosis but no prior coronary or cerebrovascular events. The report covered patient enrollment from January 2020 through June 2023 and applied a standardized two-year follow-up for eligible participants. The study team framed their analysis to detect new-onset MACE rather than recurrent events.
Investigators enrolled patients with carotid atherosclerosis confirmed by ultrasound. They excluded anyone with documented prior coronary heart disease, ischemic stroke, or transient ischemic attack so that only incident cardiovascular outcomes were captured. The abstract describes a standardized two-year follow-up for all included participants. The source did not report, in the abstract, granular details such as antiretroviral therapy (ART) regimens, viral load, or CD4 counts; those variables were not described as part of the multivariate model in the abstract.
The cohort analysis identified a younger age profile among people living with HIV: mean age in the HIV-positive group was 63.55 ± 10.81 years versus 70.61 ± 9.75 years in HIV-negative patients, a difference the study team reported as statistically significant (p < 0.001). Cumulative MACE over two years occurred more frequently in PLWH. The reported 2-year occurrence rate of MACE was 40.4% for the HIV-positive group compared with 22.9% for HIV-negative counterparts (p = 0.023). Those outcome figures reflect short-term incident cardiovascular events in a population already identified with carotid atherosclerotic disease.
The authors used univariate testing to screen variables associated with MACE and then constructed a multivariate binary logistic regression model. They entered variables with univariate p < 0.05 along with core clinical confounders—age, sex, hypertension, and diabetes. The regression identified four independent correlates of new-onset MACE during the two-year observation window:
These associations indicate an elevated short-term risk for MACE in PLWH even after adjustment for core demographic and clinical confounders included in the model as described in the abstract.
The data indicated that Chinese PLWH with carotid atherosclerosis developed measurable atherosclerotic lesions at a younger age compared with HIV-negative patients in the same center. The study team reported that HIV infection itself carried approximately a twofold increased odds of incident MACE over two years. Smoking status, renal function as measured by eGFR, and serum uric acid concentration were also independent correlates, which suggests these are actionable risk domains for clinicians managing this group.
From a clinical-management perspective, the authors recommended integrated interventions that address HIV viral control, smoking cessation, renal function protection, and serum uric acid management to improve long-term cardiovascular prognosis for this population. The abstract did not provide specific intervention protocols or thresholds for initiating therapies; it reported associations rather than trialled management strategies.
The authors used a retrospective, single-center cohort design. That design limits causal inference and reduces generalizability beyond the study setting. The abstract did not report details on antiretroviral therapy regimens, HIV virologic control, CD4 counts, medication adherence, or plaque characteristics beyond ultrasound confirmation; those variables therefore were not described in the abstract as covariates or modifiers in the multivariate model. Event adjudication methods, exact MACE components and timing within the two-year window were described only as cumulative incidence in the abstract; the report did not present additional methodological detail in the abstract text.
These gaps in the abstract—single-center sampling, retrospective design, and absent ART and immunologic data—should temper interpretation. The observed associations identify high-risk domains and patient groups for closer cardiovascular surveillance, but the study cannot establish causation or define specific therapy thresholds on its own. Further multicenter and prospectively collected data that include detailed HIV-specific variables would be needed to refine risk stratification and to test targeted interventions.